Clinical trial Recruiting at 1 site Observational Ages 18 to 65

Monocyte responses in adults with type 1 diabetes and chronic kidney disease

Official title: Monocytes in Subjects With Type 1 Diabetes and Chronic Kidney Disease

Run by The Cleveland Clinic · NCT06694558 · Data updated 2026-11-12

This study will test whether time-in-range changes how monocytes become activated in adults with type 1 diabetes and chronic kidney disease and whether a GLP-1 drug can reduce that activation in lab tests.

More Type 1 Diabetes (T1D) trials

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment60 (estimated)
SponsorThe Cleveland Clinic
Academic / other
Locations1 site (Cleveland, Ohio)
StatusRecruiting
StartedMarch 1, 2025
Main results expectedDecember 30, 2026
Study endsJuly 1, 2027
Registry record updatedJuly 8, 2026
Trial IDNCT06694558 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 18–65 with type 1 diabetes on insulin and using a continuous glucose monitor, either with CKD (eGFR 60–90 ml/min/1.73 m2 and UACR 30–500 mg/g) or as controls without CKD (eGFR >90 and UACR <30 mg/g).

Probably not a fit

People already taking GLP-1 agonists, DPP-4 inhibitors, or SGLT2 inhibitors, those with hemoglobin <9 g/dL, those not using a CGM, or individuals outside the 18–65 age range are unlikely to be eligible or to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a cross-sectional study comparing monocyte responses from adults with type 1 diabetes who have CKD to those without CKD. Participants will be stratified by continuous glucose monitor time-in-range (lower <60% vs higher >70%) and provide a blood sample during a single study visit. Monocytes will be studied ex vivo for activation and effects on podocytes, and investigators will test whether a GLP-1 agonist attenuates monocyte activation in laboratory assays. Subjects are recruited from the Cleveland Clinic and the community and may be asked to return for a repeat blood draw if initial samples do not yield enough cells.

Why it matters

Potential benefit: If successful, this work could point to time-in-range and GLP-1–related pathways as targets to reduce inflammatory processes that may worsen kidney injury in people with type 1 diabetes.

How similar studies have gone: Prior clinical and laboratory studies have reported anti-inflammatory and kidney-protective effects of GLP-1 drugs in diabetes, but applying ex vivo monocyte activation assays specifically in type 1 diabetes with CKD is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. T1D CKD subjects:

   1. Adults, males or females diagnosed with T1D
   2. Age 18-65 years
   3. Diagnosed with CKD (eGFR 60-90 ml/min/1.73 m2)
   4. Diagnosed with albuminuria (UACR 30-500 mg/g)
   5. On insulin injections or pump
   6. On CGM

   Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0
2. Controls: T1D subjects without CKD

   1. Adults, males or females diagnosed with T1D
   2. Age 18-65 years
   3. No CKD (eGFR \>90 ml/min/1.73 m2)
   4. No albuminuria (UACR \<30 mg/g)
   5. On insulin injections or pump
   6. On CGM

Based on baseline CGM metrics, the investigators will stratify subjects to 2 groups Group A (Lower TIR group): TIR\<60%, A1c 7.5-9.5 Group B (Higher TIR group): TIR\>70% A1c 5.0-7.0

Exclusion Criteria:

1. Hemoglobin \<9
2. On GLP-1 agonist or DPP4 inhibitor or sodium-glucose co-transporter-2 inhibitors use within 30 days
3. pregnancy or plans to become pregnant
4. On steroids
5. Diagnosed with cancer, immunosuppression/autoimmune conditions
6. Reported heavy alcohol use or recreational drug use
7. Any condition which jeopardizes patient safety or affects monocytes at physician's discretion

Where it's running

  • Cleveland Clinic
    Cleveland, Ohio, United States
    Recruiting

Study contacts

  • Principal investigator: Rong M Zhang, MD — The Cleveland Clinic
  • Study coordinator: Andrea Debs
  • Email: debsa@ccf.org
  • Phone: 216-445-8354

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.